Relay Therapeutics, Inc. Deferred Costs, Noncurrent
Relay Therapeutics, Inc. (RLAY) had Deferred Costs, Noncurrent of $1.12 million as of 2020-06-30, per its 10-Q filed 2020-08-27.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredCosts · last filed 2020-08-27
- 2020-06-30: Deferred Costs, Noncurrent $1.12M.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2020-06-30 | $1.12M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |